UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-11, Vol.29, p.ix23-ix23

2018

Volltextzugriff (PDF)

2309P High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment

Annals of oncology, 2023-10, Vol.34, p.S1180-S1180

2023

Volltextzugriff (PDF)

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S523-S523

2024

Volltextzugriff (PDF)

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Annals of oncology, 2024-09, Vol.35, p.S486-S487

2024

Volltextzugriff (PDF)

1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

Annals of oncology, 2023-10, Vol.34, p.S649-S650

2023

Volltextzugriff (PDF)

1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

Annals of oncology, 2023-10, Vol.34, p.S631-S631

2023

Volltextzugriff (PDF)

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

Annals of oncology, 2022-09, Vol.33, p.S751-S752

2022

Volltextzugriff (PDF)

354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)

Annals of oncology, 2022-09, Vol.33, p.S697-S698

2022

Volltextzugriff (PDF)

A Phase I Study of Cetuximab in Combination with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S250-S251

2008

Volltextzugriff (PDF)

612P - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Annals of oncology, 2019-10, Vol.30, p.v231-v231

2019

Volltextzugriff (PDF)

SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Annals of oncology, 2019-10, Vol.30, p.v231

2019

Volltextzugriff (PDF)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii133

2018

Volltextzugriff (PDF)

682P - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Annals of oncology, 2019-10, Vol.30, p.v259-v260

2019

Volltextzugriff (PDF)

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Annals of oncology, 2019-10, Vol.30, p.v162-v163

2019

Volltextzugriff (PDF)

445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Annals of oncology, 2019-10, Vol.30, p.v162-v163

2019

Volltextzugriff (PDF)

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Annals of oncology, 2019-10, Vol.30, p.v259-v260

2019

Volltextzugriff (PDF)

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-10, Vol.29, p.viii716-viii716

2018

Volltextzugriff (PDF)

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29, p.viii189-viii190

2018

Volltextzugriff (PDF)

297 POSTER Phase I and pharmacokinetic trial of SJG-136 administered on a daily × 5 schedule

European journal of cancer supplements, 2006-11, Vol.4 (12), p.93-93

2006

Volltextzugriff (PDF)

Ultrastructural aspects of early stages in cotton fiber elongation

American journal of botany, 1976-07, Vol.63 (6), p.868-876

1976

Volltextzugriff (PDF)

Differentiation of cotton fibers from single cells in suspension culture

In Vitro Cellular & Developmental Biology, 1987-11, Vol.23 (11), p.789-794

1987

Volltextzugriff (PDF)

Poly(adenosine diphosphate‐ribose) polymerase inhibitor combinations in first‐line metastatic castrate‐resistant prostate cancer setting: a systematic review and m eta‐analysis

BJU international, 2023-12, Vol.132 (6), p.619-630

2023

Volltextzugriff (PDF)

OC-0783 Is full adaptation needed for prostate stereotactic body radiotherapy? A dosimetric comparison

Radiotherapy and oncology, 2022-05, Vol.170, p.S702-S703

2022

Volltextzugriff (PDF)

535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer

Annals of oncology, 2021-09, Vol.32, p.S600-S601

2021

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(55)
Bücher
(1)

Sprache

Englisch
(55)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Particle Physics
(7)
Cell Walls
(2)
Cotton Fibers
(2)
Epidermal Cells
(2)
Abiologyamathematical Modelszautomatisch Aus Gbv_2011-10 2012-04-22
(1)
Acute Disease
(1)
Aflatoxin B1
(1)
Aflatoxins - Poisoning
(1)
Agronomy. Soil Science And Plant Productions
(1)
Ams 34-02
(1)
Ams 34cxx
(1)
Ams 35-02
(1)
Ams 92-01
(1)
Ams 92-02
(1)
Ams 92bxx
(1)
Ams 92cxx
(1)
Ams 92dxx
(1)
Animals
(1)
Applicazioni Alla Biologia
(1)
Applied Mathematics
(1)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

2309P High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)

A Phase I Study of Cetuximab in Combination with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer

612P - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

682P - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

297 POSTER Phase I and pharmacokinetic trial of SJG-136 administered on a daily × 5 schedule

Ultrastructural aspects of early stages in cotton fiber elongation

Differentiation of cotton fibers from single cells in suspension culture

Poly(adenosine diphosphate‐ribose) polymerase inhibitor combinations in first‐line metastatic castrate‐resistant prostate cancer setting: a systematic review and m eta‐analysis

OC-0783 Is full adaptation needed for prostate stereotactic body radiotherapy? A dosimetric comparison

535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer

Aktive Filter

Suchergebnisse filtern